加载页面时好像出了点问题.
我们的团队已经注意到了，但如果问题仍然存在，请使用电子邮件支持小工具联系我们。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 3.1x - 3.4x | 3.2x |
| Historical Pb Multiple | 2.4x - 6.2x | 5.0x |
| Fair Value | 0.0043A$ - 0.0048A$ | 0.0046A$ |
| Upside | -13.1% - -4.0% | -8.6% |
| Benchmarks | - | Full Ticker |
| Noxopharm Limited | - | ASX:NOX |
| Paradigm Biopharmaceuticals Limited | - | ASX:PAR |
| Alterity Therapeutics Limited | - | ASX:ATH |
| Prescient Therapeutics Limited | - | ASX:PTX |
| Cynata Therapeutics Limited | - | ASX:CYP |
| Algorae Pharmaceuticals Limited | - | ASX:1AI |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| NOX | PAR | ATH | PTX | CYP | 1AI | |||
| ASX:NOX | ASX:PAR | ASX:ATH | ASX:PTX | ASX:CYP | ASX:1AI | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 80.9% | 79.2% | -61.1% | 8.7% | 35.1% | 42.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -178.1% | -125344.1% | -8988.1% | -284.4% | -333.6% | -11796.9% | ||
| Prior Fiscal Year | -250.5% | NA | -352.5% | -288.5% | -863.0% | -5016.3% | ||
| Latest Fiscal Year | -149.1% | NA | -475.8% | -221.9% | -420.8% | -1673.8% | ||
| Latest Twelve Months | -98.8% | -87172.0% | -531.3% | -234.0% | -508.8% | -1036.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -55.5% | -72.7% | -73.2% | -28.5% | -48.7% | -56.9% | ||
| Prior Fiscal Year | -90.7% | -108.2% | -47.4% | -32.7% | -70.2% | -54.1% | ||
| Latest Twelve Months | -42.5% | -42.9% | -155.8% | -37.0% | -74.5% | -43.2% | ||
| Next Fiscal Year | #NUM! | 24754.6% | -502.5% | -172.1% | -278.4% | #NUM! | ||
| Two Fiscal Years Forward | -96.5% | 115.0% | 130.6% | 176.7% | 91.6% | -3302.0% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 10.8x | 9094.4x | 13.3x | 11.5x | 25.3x | 67.4x | ||
| Price / LTM EPS | -11.0x | -10.4x | -2.5x | -4.9x | -5.0x | -6.5x | ||
| Price / Book | 5.9x | 4.5x | 6.3x | 2.2x | 3.8x | 3.5x | ||
| Price / Fwd Book | 4.6x | -6.2x | -8.3x | 25.5x | -37.3x | 2.8x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 2.2x | 4.5x | 6.3x | |||||
| Historical P/B Ratio | 2.4x | 5.0x | 6.2x | |||||
| Selected P/B Multiple | 3.1x | 3.2x | 3.4x | |||||
| (x) Book Value | 2 | 2 | 2 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | NOX | PAR | ATH | PTX | CYP | 1AI | |
| Value of Common Equity | 25 | 150 | 49 | 35 | 44 | 8 | |
| (/) Shares Outstanding | 292.2 | 389.4 | 5,491.0 | 805.3 | 226.0 | 1,687.4 | |
| Implied Stock Price | 0.09 | 0.39 | 0.01 | 0.04 | 0.20 | 0.01 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.09 | 0.39 | 0.01 | 0.04 | 0.20 | 0.01 | |
| Trading Currency | AUD | AUD | AUD | AUD | AUD | AUD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |